2025 · Poster Presentation · Genentech · Hepatology
Vice President, Scientific & Medical Affairs, Real World Evidence
Andrea R. Mospan
Andrea Rossi Mospan, PhD, RAC, is currently serving as Vice President, Scientific & Medical Affairs, Real World Evidence at Target RWE, and works closely with pharmaceutical partners and key opinion leaders, as well as the cross functional medical affairs, epidemiology, statistical, clinical and data science teams at Target RWE.
Dr. Mospan has over 16 years of experience in the pharmaceutical industry including medical and scientific affairs, clinical development, and regulatory affairs. Previously she was an Associate Director in clinical development at a mid-size pharmaceutical company, Inspire Pharmaceuticals, and led regulatory submissions for integrated product development programs as well as clinical trials as a Senior Research Scientist at a full-service CRO, Rho Inc. Dr. Mospan received a doctorate in Cell and Molecular Physiology from the University of North Carolina at Chapel Hill and has contributed as a co-author to more than 15 manuscripts in addition to over 20 abstracts.

Publications
52
Total Publications
2025 · Abstract/Manuscript · UNC
The Magnitude of Polypharmacy and Role of Disease Severity and Patient Sex in Medication Use Among Patients With MASLD Enrolled in TARGET-NASH
Read more →2025 · Abstract/Manuscript · Kings College of London
Cardiovascular risk assessment tools are insufficient for patients with metabolic dysfunction associated steatotic liver disease
Read more →2025 · Abstract/Manuscript
DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral Therapy
Read more →2025 · Poster Presentation · University of Miami (FL) · Hepatology
Changes in The Fibrosis-4 (FIB-4) Score Accurately Reflects The Disease Trajectory of Metabolic Dysfunction Associated Steatotic Liver Disease
Read more →2025 · Poster Presentation · Saint Louis University · Hepatology
Clinical Characteristics of Patients With Presumed MASLD Who Meet Met-ALD Criteria in the TARGET-NASH Cohort
Read more →2025 · Poster Presentation · Madrigal · Hepatology
Relationship between non-invasive tests, clinical outcomes and liver biopsy among people with MASH under real-world conditions
Read more →2025 · Poster Presentation · German Diabetes Center (DDZ) / Heinrich Heine University Düsseldorf · Hepatology
Type 2 Diabetes and Obesity are The Main Metabolic Risk Factors for The Development of Cirrhosis in People with Metabolic Dysfunction Associated Steatohepatitis
Read more →2024 · Poster Presentation · German Diabetes Center (DDZ) / Heinrich Heine University Düsseldorf · Hepatology
Type 2 diabetes increases the risk of progression to metabolic dysfunction-associated steatohepatitis-related cirrhosis in a real world setting
Read more →2024 · Poster Presentation · University of Birmingham UK · Hepatology
Stability of the NASH-CHECK patient-reported outcome measure over time in patients with metabolic dysfunction-associated steatotic liver disease and stable clinical status
Read more →2024 · Poster Presentation · UNC · Hepatology
A prospective assessment of the impact of decompensation of cirrhosis on patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease
Read more →2024 · Poster Presentation · Merck · Hepatology
Time to Disease Progression and All-Cause Mortality in Adult MASH Patients in Real-World US Cohort
Read more →2024 · Poster Presentation · Merck · Hepatology
Characteristics of adult MASH patients and factors associated with MASH-relevant clinical endpoints in a real-world US cohort
Read more →2024 · Poster Presentation · Novo Nordisk · Hepatology
Understanding Metabolic Dysfunction-Associated Steatohepatitis: Differences in Clinical and Demographic Characteristics Across Racial and Ethnic Groups
Read more →2024 · Poster Presentation · UNC · Hepatology
Use of sodium-glucose transport protein 2 inhibitors and dipeptidyl peptidase 4 inhibitors in patients with MASLD in a real-world setting is associated with lower all-cause mortality
Read more →2024 · Poster Presentation · University of Birmingham UK · Hepatology
Real-World Use of Glucagon-Like Peptide 1 Receptor Agonists in Patients with MASLD: A Cross-Sectional Analysis from TARGET-NASH
Read more →2024 · Poster Presentation · Saint Louis University · Hepatology
A prospective assessment of disease progression impact on patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease
Read more →2024 · Poster Presentation · Madrigal · Hepatology
Non-invasive tests as a prediction tool to assess MASH resolution score
Read more →2024 · Poster Presentation · Madrigal · Hepatology
A longitudinal assessment of cardiovascular risk for NASH/MASH patients enrolled in TARGET-NASH
Read more →2024 · Poster Presentation · University of Miami (FL) · Hepatology
Complication-Free Survival in a Real-World Cohort of PBC Patients: Deep Versus Adequate ALP Response to UDCA
Read more →2024 · Abstract/Manuscript · Duke
Concordance of MASLD and NAFLD nomenclature in youth participating in the TARGET-NASH real-world cohort
Read more →2024 · Abstract/Manuscript · Heinrich Heine University Dusseldorf/German Diabetes Center
High Concordance Between Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease in the TARGET-NASH Real-World Cohort
Read more →2024 · Poster Presentation · Heinrich Heine University Düsseldorf · Hepatology
Relationship between liver biopsy fibrosis stage and clinical outcomes among persons with MASLD/MASH
Read more →2024 · Oral Presentation · Saint Louis University · Hepatology
Use of glucagon-like peptide 1 receptor agonists in patients with MASLD in a real-world setting is associated with slower disease progression and lower all-cause mortality
Read more →2023 · Poster Presentation · University of Birmingham / NIHR Birmingham BRC · Hepatology
NASH Progression Rates Based on Fibrosis and Inflammation (NAS): A Paired Biopsy Analysis From a Natural History Cohort in the US
Read more →2023 · Poster Presentation · Cleveland Clinic · Hepatology
A Prospective, Pragmatic Post-Authorisation Safety Study of Early Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus-Infected Patients after Direct-Acting Antiviral (DAA) Therapy: DAA-PASS
Read more →2023 · Poster Presentation · University of Birmingham (UK) · Methods/Pharmacoepi
Analysis of discrimination and calibration of two cardiovascular risk scores in patients with non-alcoholic steatohepatitis shows a need for improved accuracy of these models
Read more →2023 · Abstract/Manuscript · National University Hospital
Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort
Read more →2023 · Abstract/Manuscript · Mayo Clinic
Impact of itch on quality of life in people with primary biliary cholangitis: a plain language summary
Read more →2023 · Oral Presentation · Hepatology
Non-alcoholic Steatohepatitis Disease Progression in Participants from the United States TARGET-NASH Real World Longitudinal Observational Study
Read more →2023 · Abstract/Manuscript · University of North Carolina at Chapel Hill
Effectiveness of Remdesivir Treatment Protocols Among Patients Hospitalized with COVID-19: A Target Trial Emulation
Read more →2022 · Poster Presentation · Saint Louis University · Hepatology
The Role of Disease Severity and Gender in Polypharmacy Among Patients with NAFLD Enrolled in TARGET-NASH
Read more →2022 · Poster Presentation · Novartis · Hepatology
Longitudinal ALT Trajectories are Generally Stable Among Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): An Investigation Using Artificial Recurrent Neural Networks
Read more →2022 · Poster Presentation · Methods/Pharmacoepi
Healthcare Utilization and Charges Associated with US Hospitalized Adult Patients with COVID 19
Read more →2022 · Poster Presentation · Methods/Pharmacoepi
Association Between Clinical Outcomes and Patient Characteristics Among Hospitalized Adult Patients with COVID-19
Read more →2022 · Abstract/Manuscript · Emory
Variation in Alanine Aminotransferase in Children with Non-Alcoholic Fatty Liver Disease
Read more →2022 · Abstract/Manuscript · Mayo Clinic
Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis
Read more →2022 · Oral Presentation · Hepatology
Pruritus in Primary Biliary Cholangitis is Under-Treated in Clinical Practice: Results from TARGET-PBC (APASL)
Read more →2022 · Oral Presentation · Hepatology
The Pervasive Impact of Pruritus on Quality of Life in Patients with Primary Biliary Cholangitis (PBC): Real World Experience in TARGET-PBC (APASL)
Read more →2021 · Poster Presentation · AbbVie · Hepatology
Determination of Optimal Thresholds for Significant Fibrosis in NAFLD Using Non-Invasive Tests from TARGET-NASH Study
Read more →2021 · Abstract/Manuscript · Heinrich Heine University Düsseldorf
Liver Biopsy in the Real World—Reporting, Expert Concordance and Correlation with a Pragmatic Clinical Diagnosis
Read more →2021 · Abstract/Manuscript · Heinrich Heine University Düsseldorf
Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study
Read more →2021 · Abstract/Manuscript · University of Michigan
Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study
Read more →2021 · Abstract/Manuscript · University of Michigan
Weight Loss and Weight Regain in Usual Clinical Practice: Results from the TARGET-NASH Observational Cohort
Read more →2021 · Abstract/Manuscript · Zucker School of Medicine at Hofstra
Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV
Read more →2021 · Abstract/Manuscript · University of North Carolina at Chapel Hill
Factors Associated with Readmission in the US Following Hospitalization with COVID-19
Read more →2020 · Poster Presentation · Heinrich-Heine University Düsseldorf · Hepatology
Heterogeneous Documentation and Poor Concordance of NASH Pathology May Limit its Clinical Utility in Real-World Practice
Read more →2020 · Poster Presentation · UNC · Hepatology
Fibrosis Assessed by Non-Invasive Tests is Similar to Liver Biopsy for Predicting Clinical Outcomes: A TARGET-NASH Study
Read more →2020 · Abstract/Manuscript · University of Michigan
A Real-World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET-HCC
Read more →2020 · Oral Presentation · Hepatology
Clinical Profile of Nonalcoholic Fatty Liver Disease in Adults with Type 2 Diabetes Mellitus
Read more →2020 · Abstract/Manuscript · University of North Carolina at Chapel Hill
Patient Characteristics and Outcomes of 11,721 Patients with COVID19 Hospitalized Across the United States
Read more →2019 · Poster Presentation · University of Pennsylvania · Methods/Pharmacoepi